Figure SF4 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study Article Swipe

View

Yasutoshi Kuboki , Toshio Shimizu , Kan Yonemori , Takashi Kojima , Shunsuke Kondo , Shigehiro Koganemaru , Satoru Iwasa , Kenichi Harano , Takafumi Koyama , Vickie Lu , Xiaofei Zhou , Huifeng Niu , Tomoko Yanai , Ignacio Garcia‐Ribas , Toshihiko Doi , Noboru Yamamoto ·

YOU? · · 2023 · Open Access · · DOI: https://doi.org/10.1158/2767-9764.22545071

(A) Best percent change from baseline in tumor size for all patients in schedule A. (B) and (C) computed tomography scans from patients in schedule A at screening (left panels) and 9 weeks post-dose (right panels); (B) patient with duodenal cancer treated with TAK-931 30 mg; (C) patient with esophageal cancer treated with TAK-931 50 mg. Yellow arrows indicate target lesions.

Related Topics

Concepts

Tolerability Pharmacokinetics Schedule Medicine Computed tomography Internal medicine Nuclear medicine Oncology Pharmacology Radiology Adverse effect Computer science Operating system

Metadata

Type: preprint
Language: en
Landing Page: https://doi.org/10.1158/2767-9764.22545071
OA Status: gold
Related Works: 10
OpenAlex ID: https://openalex.org/W4362619614

All OpenAlex metadata

Raw OpenAlex JSON

OpenAlex ID: https://openalex.org/W4362619614

Canonical identifier for this work in OpenAlex
DOI: https://doi.org/10.1158/2767-9764.22545071

Digital Object Identifier
Title: Figure SF4 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

Work title
Type: preprint

OpenAlex work type
Language: en

Primary language
Publication year: 2023

Year of publication
Publication date: 2023-04-04

Full publication date if available
Authors: Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, Shigehiro Koganemaru, Satoru Iwasa, Kenichi Harano, Takafumi Koyama, Vickie Lu, Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia‐Ribas, Toshihiko Doi, Noboru Yamamoto

List of authors in order
Landing page: https://doi.org/10.1158/2767-9764.22545071

Publisher landing page
Open access: Yes

Whether a free full text is available
OA status: gold

Open access status per OpenAlex
OA URL: https://doi.org/10.1158/2767-9764.22545071

Direct OA link when available
Concepts: Tolerability, Pharmacokinetics, Schedule, Medicine, Computed tomography, Internal medicine, Nuclear medicine, Oncology, Pharmacology, Radiology, Adverse effect, Computer science, Operating system

Top concepts (fields/topics) attached by OpenAlex
Cited by: 0

Total citation count in OpenAlex
Related works (count): 10

Other works algorithmically related by OpenAlex

Full payload

id	https://openalex.org/W4362619614
doi	https://doi.org/10.1158/2767-9764.22545071
ids.doi	https://doi.org/10.1158/2767-9764.22545071
ids.openalex	https://openalex.org/W4362619614
fwci	0.0
type	preprint
title	Figure SF4 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
biblio.issue
biblio.volume
biblio.last_page
biblio.first_page
topics[0].id	https://openalex.org/T13110
topics[0].field.id	https://openalex.org/fields/27
topics[0].field.display_name	Medicine
topics[0].score	0.9532999992370605
topics[0].domain.id	https://openalex.org/domains/4
topics[0].domain.display_name	Health Sciences
topics[0].subfield.id	https://openalex.org/subfields/2746
topics[0].subfield.display_name	Surgery
topics[0].display_name	Colorectal and Anal Carcinomas
topics[1].id	https://openalex.org/T11067
topics[1].field.id	https://openalex.org/fields/27
topics[1].field.display_name	Medicine
topics[1].score	0.9527000188827515
topics[1].domain.id	https://openalex.org/domains/4
topics[1].domain.display_name	Health Sciences
topics[1].subfield.id	https://openalex.org/subfields/2730
topics[1].subfield.display_name	Oncology
topics[1].display_name	Colorectal Cancer Treatments and Studies
topics[2].id	https://openalex.org/T10231
topics[2].field.id	https://openalex.org/fields/27
topics[2].field.display_name	Medicine
topics[2].score	0.9229999780654907
topics[2].domain.id	https://openalex.org/domains/4
topics[2].domain.display_name	Health Sciences
topics[2].subfield.id	https://openalex.org/subfields/2730
topics[2].subfield.display_name	Oncology
topics[2].display_name	Pancreatic and Hepatic Oncology Research
is_xpac	False
apc_list
apc_paid
concepts[0].id	https://openalex.org/C2778375690
concepts[0].level	3
concepts[0].score	0.8316177129745483
concepts[0].wikidata	https://www.wikidata.org/wiki/Q7814214
concepts[0].display_name	Tolerability
concepts[1].id	https://openalex.org/C112705442
concepts[1].level	2
concepts[1].score	0.7135285139083862
concepts[1].wikidata	https://www.wikidata.org/wiki/Q323936
concepts[1].display_name	Pharmacokinetics
concepts[2].id	https://openalex.org/C68387754
concepts[2].level	2
concepts[2].score	0.6180501580238342
concepts[2].wikidata	https://www.wikidata.org/wiki/Q7271585
concepts[2].display_name	Schedule
concepts[3].id	https://openalex.org/C71924100
concepts[3].level	0
concepts[3].score	0.5613747239112854
concepts[3].wikidata	https://www.wikidata.org/wiki/Q11190
concepts[3].display_name	Medicine
concepts[4].id	https://openalex.org/C544519230
concepts[4].level	2
concepts[4].score	0.447546124458313
concepts[4].wikidata	https://www.wikidata.org/wiki/Q32566
concepts[4].display_name	Computed tomography
concepts[5].id	https://openalex.org/C126322002
concepts[5].level	1
concepts[5].score	0.42816826701164246
concepts[5].wikidata	https://www.wikidata.org/wiki/Q11180
concepts[5].display_name	Internal medicine
concepts[6].id	https://openalex.org/C2989005
concepts[6].level	1
concepts[6].score	0.3966815173625946
concepts[6].wikidata	https://www.wikidata.org/wiki/Q214963
concepts[6].display_name	Nuclear medicine
concepts[7].id	https://openalex.org/C143998085
concepts[7].level	1
concepts[7].score	0.36537396907806396
concepts[7].wikidata	https://www.wikidata.org/wiki/Q162555
concepts[7].display_name	Oncology
concepts[8].id	https://openalex.org/C98274493
concepts[8].level	1
concepts[8].score	0.3220673203468323
concepts[8].wikidata	https://www.wikidata.org/wiki/Q128406
concepts[8].display_name	Pharmacology
concepts[9].id	https://openalex.org/C126838900
concepts[9].level	1
concepts[9].score	0.2743838429450989
concepts[9].wikidata	https://www.wikidata.org/wiki/Q77604
concepts[9].display_name	Radiology
concepts[10].id	https://openalex.org/C197934379
concepts[10].level	2
concepts[10].score	0.25845521688461304
concepts[10].wikidata	https://www.wikidata.org/wiki/Q2047938
concepts[10].display_name	Adverse effect
concepts[11].id	https://openalex.org/C41008148
concepts[11].level	0
concepts[11].score	0.0
concepts[11].wikidata	https://www.wikidata.org/wiki/Q21198
concepts[11].display_name	Computer science
concepts[12].id	https://openalex.org/C111919701
concepts[12].level	1
concepts[12].score	0.0
concepts[12].wikidata	https://www.wikidata.org/wiki/Q9135
concepts[12].display_name	Operating system
keywords[0].id	https://openalex.org/keywords/tolerability
keywords[0].score	0.8316177129745483
keywords[0].display_name	Tolerability
keywords[1].id	https://openalex.org/keywords/pharmacokinetics
keywords[1].score	0.7135285139083862
keywords[1].display_name	Pharmacokinetics
keywords[2].id	https://openalex.org/keywords/schedule
keywords[2].score	0.6180501580238342
keywords[2].display_name	Schedule
keywords[3].id	https://openalex.org/keywords/medicine
keywords[3].score	0.5613747239112854
keywords[3].display_name	Medicine
keywords[4].id	https://openalex.org/keywords/computed-tomography
keywords[4].score	0.447546124458313
keywords[4].display_name	Computed tomography
keywords[5].id	https://openalex.org/keywords/internal-medicine
keywords[5].score	0.42816826701164246
keywords[5].display_name	Internal medicine
keywords[6].id	https://openalex.org/keywords/nuclear-medicine
keywords[6].score	0.3966815173625946
keywords[6].display_name	Nuclear medicine
keywords[7].id	https://openalex.org/keywords/oncology
keywords[7].score	0.36537396907806396
keywords[7].display_name	Oncology
keywords[8].id	https://openalex.org/keywords/pharmacology
keywords[8].score	0.3220673203468323
keywords[8].display_name	Pharmacology
keywords[9].id	https://openalex.org/keywords/radiology
keywords[9].score	0.2743838429450989
keywords[9].display_name	Radiology
keywords[10].id	https://openalex.org/keywords/adverse-effect
keywords[10].score	0.25845521688461304
keywords[10].display_name	Adverse effect
language	en
locations[0].id	doi:10.1158/2767-9764.22545071
locations[0].is_oa	True
locations[0].source
locations[0].license	cc-by
locations[0].pdf_url
locations[0].version	acceptedVersion
locations[0].raw_type	posted-content
locations[0].license_id	https://openalex.org/licenses/cc-by
locations[0].is_accepted	True
locations[0].is_published	False
locations[0].raw_source_name
locations[0].landing_page_url	https://doi.org/10.1158/2767-9764.22545071
indexed_in	crossref
authorships[0].author.id	https://openalex.org/A5060366426
authorships[0].author.orcid	https://orcid.org/0000-0003-3675-953X
authorships[0].author.display_name	Yasutoshi Kuboki
authorships[0].author_position	first
authorships[0].raw_author_name	Yasutoshi Kuboki
authorships[0].is_corresponding	False
authorships[1].author.id	https://openalex.org/A5046628885
authorships[1].author.orcid	https://orcid.org/0000-0001-6632-0638
authorships[1].author.display_name	Toshio Shimizu
authorships[1].author_position	middle
authorships[1].raw_author_name	Toshio Shimizu
authorships[1].is_corresponding	False
authorships[2].author.id	https://openalex.org/A5021522674
authorships[2].author.orcid	https://orcid.org/0000-0002-7624-7611
authorships[2].author.display_name	Kan Yonemori
authorships[2].author_position	middle
authorships[2].raw_author_name	Kan Yonemori
authorships[2].is_corresponding	False
authorships[3].author.id	https://openalex.org/A5060944214
authorships[3].author.orcid	https://orcid.org/0000-0001-7721-1031
authorships[3].author.display_name	Takashi Kojima
authorships[3].author_position	middle
authorships[3].raw_author_name	Takashi Kojima
authorships[3].is_corresponding	False
authorships[4].author.id	https://openalex.org/A5080299485
authorships[4].author.orcid	https://orcid.org/0000-0001-9565-117X
authorships[4].author.display_name	Shunsuke Kondo
authorships[4].author_position	middle
authorships[4].raw_author_name	Shunsuke Kondo
authorships[4].is_corresponding	False
authorships[5].author.id	https://openalex.org/A5068779813
authorships[5].author.orcid	https://orcid.org/0000-0003-1323-4896
authorships[5].author.display_name	Shigehiro Koganemaru
authorships[5].author_position	middle
authorships[5].raw_author_name	Shigehiro Koganemaru
authorships[5].is_corresponding	False
authorships[6].author.id	https://openalex.org/A5067881155
authorships[6].author.orcid	https://orcid.org/0000-0003-3863-9582
authorships[6].author.display_name	Satoru Iwasa
authorships[6].author_position	middle
authorships[6].raw_author_name	Satoru Iwasa
authorships[6].is_corresponding	False
authorships[7].author.id	https://openalex.org/A5000514150
authorships[7].author.orcid	https://orcid.org/0000-0002-0833-3489
authorships[7].author.display_name	Kenichi Harano
authorships[7].author_position	middle
authorships[7].raw_author_name	Kenichi Harano
authorships[7].is_corresponding	False
authorships[8].author.id	https://openalex.org/A5041593880
authorships[8].author.orcid	https://orcid.org/0000-0001-5807-8458
authorships[8].author.display_name	Takafumi Koyama
authorships[8].author_position	middle
authorships[8].raw_author_name	Takafumi Koyama
authorships[8].is_corresponding	False
authorships[9].author.id	https://openalex.org/A5022975853
authorships[9].author.orcid
authorships[9].author.display_name	Vickie Lu
authorships[9].author_position	middle
authorships[9].raw_author_name	Vickie Lu
authorships[9].is_corresponding	False
authorships[10].author.id	https://openalex.org/A5103978699
authorships[10].author.orcid
authorships[10].author.display_name	Xiaofei Zhou
authorships[10].author_position	middle
authorships[10].raw_author_name	Xiaofei Zhou
authorships[10].is_corresponding	False
authorships[11].author.id	https://openalex.org/A5006765090
authorships[11].author.orcid	https://orcid.org/0000-0003-1486-1509
authorships[11].author.display_name	Huifeng Niu
authorships[11].author_position	middle
authorships[11].raw_author_name	Huifeng Niu
authorships[11].is_corresponding	False
authorships[12].author.id	https://openalex.org/A5010342212
authorships[12].author.orcid	https://orcid.org/0000-0002-2753-5078
authorships[12].author.display_name	Tomoko Yanai
authorships[12].author_position	middle
authorships[12].raw_author_name	Tomoko Yanai
authorships[12].is_corresponding	False
authorships[13].author.id	https://openalex.org/A5062634793
authorships[13].author.orcid	https://orcid.org/0009-0003-9911-7371
authorships[13].author.display_name	Ignacio Garcia‐Ribas
authorships[13].author_position	middle
authorships[13].raw_author_name	Ignacio Garcia-Ribas
authorships[13].is_corresponding	False
authorships[14].author.id	https://openalex.org/A5001115937
authorships[14].author.orcid	https://orcid.org/0000-0003-2042-6829
authorships[14].author.display_name	Toshihiko Doi
authorships[14].author_position	middle
authorships[14].raw_author_name	Toshihiko Doi
authorships[14].is_corresponding	False
authorships[15].author.id	https://openalex.org/A5030587345
authorships[15].author.orcid	https://orcid.org/0000-0002-0787-2851
authorships[15].author.display_name	Noboru Yamamoto
authorships[15].author_position	last
authorships[15].raw_author_name	Noboru Yamamoto
authorships[15].is_corresponding	False
has_content.pdf	False
has_content.grobid_xml	False
is_paratext	False
open_access.is_oa	True
open_access.oa_url	https://doi.org/10.1158/2767-9764.22545071
open_access.oa_status	gold
open_access.any_repository_has_fulltext	False
created_date	2025-10-10T00:00:00
display_name	Figure SF4 from Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study
has_fulltext	False
is_retracted	False
updated_date	2025-11-06T03:46:38.306776
primary_topic.id	https://openalex.org/T13110
primary_topic.field.id	https://openalex.org/fields/27
primary_topic.field.display_name	Medicine
primary_topic.score	0.9532999992370605
primary_topic.domain.id	https://openalex.org/domains/4
primary_topic.domain.display_name	Health Sciences
primary_topic.subfield.id	https://openalex.org/subfields/2746
primary_topic.subfield.display_name	Surgery
primary_topic.display_name	Colorectal and Anal Carcinomas
related_works	https://openalex.org/W4379260174, https://openalex.org/W2285479586, https://openalex.org/W2087240036, https://openalex.org/W2027337507, https://openalex.org/W2169611781, https://openalex.org/W2789708638, https://openalex.org/W2037576960, https://openalex.org/W4253098345, https://openalex.org/W2196822012, https://openalex.org/W2396178441
cited_by_count	0
locations_count	1
best_oa_location.id	doi:10.1158/2767-9764.22545071
best_oa_location.is_oa	True
best_oa_location.source
best_oa_location.license	cc-by
best_oa_location.pdf_url
best_oa_location.version	acceptedVersion
best_oa_location.raw_type	posted-content
best_oa_location.license_id	https://openalex.org/licenses/cc-by
best_oa_location.is_accepted	True
best_oa_location.is_published	False
best_oa_location.raw_source_name
best_oa_location.landing_page_url	https://doi.org/10.1158/2767-9764.22545071
primary_location.id	doi:10.1158/2767-9764.22545071
primary_location.is_oa	True
primary_location.source
primary_location.license	cc-by
primary_location.pdf_url
primary_location.version	acceptedVersion
primary_location.raw_type	posted-content
primary_location.license_id	https://openalex.org/licenses/cc-by
primary_location.is_accepted	True
primary_location.is_published	False
primary_location.raw_source_name
primary_location.landing_page_url	https://doi.org/10.1158/2767-9764.22545071
publication_date	2023-04-04
publication_year	2023
referenced_works_count	0
abstract_inverted_index.9	31
abstract_inverted_index.A	25
abstract_inverted_index.30	44
abstract_inverted_index.50	54
abstract_inverted_index.A.	14
abstract_inverted_index.at	26
abstract_inverted_index.in	6, 12, 23
abstract_inverted_index.(B)	15, 36
abstract_inverted_index.(C)	17, 46
abstract_inverted_index.all	10
abstract_inverted_index.and	16, 30
abstract_inverted_index.for	9
abstract_inverted_index.mg.	55
abstract_inverted_index.mg;	45
abstract_inverted_index.Best	1
abstract_inverted_index.from	4, 21
abstract_inverted_index.size	8
abstract_inverted_index.with	38, 42, 48, 52
abstract_inverted_index.(left	28
abstract_inverted_index.scans	20
abstract_inverted_index.tumor	7
abstract_inverted_index.weeks	32
abstract_inverted_index.(right	34
abstract_inverted_index.Yellow	56
abstract_inverted_index.arrows	57
abstract_inverted_index.cancer	40, 50
abstract_inverted_index.change	3
abstract_inverted_index.target	59
abstract_inverted_index.TAK-931	43, 53
abstract_inverted_index.panels)	29
abstract_inverted_index.patient	37, 47
abstract_inverted_index.percent	2
abstract_inverted_index.treated	41, 51
abstract_inverted_index.baseline	5
abstract_inverted_index.computed	18
abstract_inverted_index.duodenal	39
abstract_inverted_index.indicate	58
abstract_inverted_index.panels);	35
abstract_inverted_index.patients	11, 22
abstract_inverted_index.schedule	13, 24
abstract_inverted_index.post-dose	33
abstract_inverted_index.screening	27
abstract_inverted_index.esophageal	49
abstract_inverted_index.tomography	19
abstract_inverted_index.<p>(A)	0
abstract_inverted_index.lesions.</p>	60
cited_by_percentile_year
countries_distinct_count	0
institutions_distinct_count	16
sustainable_development_goals[0].id	https://metadata.un.org/sdg/3
sustainable_development_goals[0].score	0.6000000238418579
sustainable_development_goals[0].display_name	Good health and well-being
citation_normalized_percentile.value	0.10885996
citation_normalized_percentile.is_in_top_1_percent	False
citation_normalized_percentile.is_in_top_10_percent	False